Servi­er says its next IDH in­hibitor has passed PhI­II, but no reg­u­la­to­ry time­line yet

Servi­er’s IDH in­hibitor vo­rasi­denib has passed its Phase III tri­al in low-grade glioma, the com­pa­ny an­nounced Tues­day morn­ing. How­ev­er, it left its reg­u­la­to­ry time­line up in the air.

The drug met the pri­ma­ry end­point of pro­gres­sion-free sur­vival as well as a sec­ondary end­point of time to next in­ter­ven­tion, Servi­er said. But when asked for more de­tails in an in­ter­view with End­points News, Servi­er’s VP of clin­i­cal de­vel­op­ment Su­san Pandya de­clined to com­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.